statnews.com·Jun 4, 2026
AI leaders are advocating for DNA safeguards in Congress, while biotech developments include a partnership between Inceptive Nucleics and Alnylam, and insights on the implications of Grail's recent trial results.
Jakob Uszkoreit, an AI pioneer who contributed to the development of transformer architecture, is now focusing on Inceptive Nucleics, a startup utilizing AI to build biological foundation models for sequence-based medicines, including RNA interference therapies. This represents a significant innovation in AI drug discovery, potentially transforming the development of RNAi, mRNA, and antisense drugs, suggesting a promising area for investment and collaboration in healthtech and biotech.